A Two-way Communication System to Coach Elderly Patients With Heart Failure (CardioCoach)

Hasselt University

Status

Completed

Conditions

Heart Failure

Treatments

Device: Telemonitoring

Study type

Interventional

Funder types

Other

Identifiers

NCT03294811

Cardiocoach

Details and patient eligibility

About

This is an open randomized clinical trial with two study arms. One group, receiving usual care for heart failure, will be compared to another group, receiving usual care plus active telemonitoring interference.

When leaving the hospital, the usual care arm receives a document with a predefined medication scheme and advice for the general practitioner (like it is currently done in usual care).

The telemonitoring interference in the other study arm consists of a smartphone application to register medication intake and to transmit the data of an automatic blood pressure device and a balance to a central platform. The goal is to improve medication uptitration (angiotensin-converting-enzyme inhibitor (ACE-I) and bètablockers (BB)) in heart failure patients and to improve medication compliance.

Enrollment

25 patients

Sex

All

Ages

60+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age ≥ 60
Patient has to be followed in Ziekenhuis Oost-Limburg or Jessa Ziekenhuis Hasselt and has to live in the region Genk - Hasselt
The patient has to be cognitive strong enough and speak enough Dutch to communicate about their health situation and to understand the smartphone application
The diagnosis of systolic heart failure or severe myocardial infarction has to be done during consultation or hospitalization
Left ventricular ejection fraction (LVEF) <45%
Treatment minimally with ACE-I and BB On the basis of an interview between the heart failure nurse and patient, one will decide if the patient is eligible to join the study. The patient also needs to speak sufficient Dutch to be communicative about his/her medical condition.

Exclusion criteria

Reversible form of heart failure
Heart failure due to severe aortic stenosis
At the time of inclusion a eGFR less than 30ml/min/kg
Presence of a cardiac resynchronization therapy (CRT) device
Active treatment with either ACE-I/ARB or BB
Patient that are subscribed in a cardiac revalidation program when leaving the hospital
Patients with severe form of COPD (GOLD III)